Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab
Authors:
- Camilla ZecchettoCZCamilla Zecchetto
- Alberto QuinziiAQAlberto Quinzii
- Simona CasalinoSCSimona Casalino
- Marina GauleMGMarina Gaule
- Camilla PesoniCPCamilla Pesoni
- Valeria MerzValeria Merz
- Silvia PietrobonoSPSilvia Pietrobono
- Domenico MangiameliDMDomenico Mangiameli
- Martina PasquatoMPMartina Pasquato
- Stefano MilleriSMStefano Milleri
- Simone GiacopuzziSGSimone Giacopuzzi
- Maria BencivengaMaria Bencivenga
Open Access
- 11 March 2023
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (3) , 508
Abstract
Trastuzumab plus chemotherapy is the standard of care for the first-line treatment of patients with HER2+ advanced esophagogastric (EG) cancer. Nevertheless, patients frequently develop resistance. In preclinical models, we identified the overexpression of Fibroblast Growth Factor Receptor (FGFR) 3 as a mechanism potentially involved in trastuzumab-acquired resistance. FGFR inhibition could be a potential mechanism as a second-line treatment. In this Simon’s two-stage phase 2, single arm study, patients with advanced EG cancer refractory to trastuzumab-containing therapies received pemigatinib, an inhibitor of FGFR. The primary end point was the 12-week progression-free survival rate. Translational analyses were performed on tissue and plasma samples. Eight patients were enrolled in the first stage. Although the 6-week disease control rate was 25%, only one patient achieved a stable disease after 12 weeks of treatment. The trial was discontinued before the second stage. Two out of six evaluable tumor samples expressed FGFR3. No FGFRs amplification was detected. HER2 amplification was lost in three out of eight patients. Three patients had an high Tumor Mutational Burden, and two of them are significantly long-term survivors. These results do not support the therapeutic efficacy of targeting FGFR in unselected patients with advanced EG cancer, who are refractory to trastuzumab-containing therapies.Keywords
Funding Information
- Incyte (n°23719, GR-2016-02361134)
- Associazione Italiana per la Ricerca sul Cancro (AIRC) (n°23719, GR-2016-02361134)
- Italian Ministry of Health through the Ricerca Finalizzata 2016 (n°23719, GR-2016-02361134)
- patients associations “Nastro Viola” and “Voglio il Massimo” (n°23719, GR-2016-02361134)
This publication has 23 references indexed in Scilit:
- Genetic Predictors of Response to Systemic Therapy in Esophagogastric CancerCancer Discovery, 2018
- Integrated genomic characterization of oesophageal carcinomaNature, 2017
- An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer PatientsClinical Cancer Research, 2016
- High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical TrialCancer Discovery, 2016
- Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding siteNature, 2015
- Targeting FGFR Signaling in CancerClinical Cancer Research, 2015
- Comprehensive molecular characterization of gastric adenocarcinomaNature, 2014
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targetsGut, 2012
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989